TAFLUPROST
本记录确认了用于欧盟化妆品标签标示的官方通用成分名称。它本身并不能确认该物质获准使用、不受限制或安全。
全球证据概览
所解析的身份在 13 个已索引市场数据集中的 1 个有匹配的监管证据:1 条国家记录和 0 条欧盟附件记录。下方列出每项结果和证据缺口。
已解析的物质身份
Isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1- enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate
3 个匹配或报告的名称
全部 13 个市场的监管证据
打开每条匹配记录,查看其范围、浓度、条件、警示语和官方来源版本。
滑动或横向滚动以查看数据集覆盖范围和后续操作。
| 市场 | 结果 | 记录 | 数据集 | 含义 / 后续操作 |
|---|---|---|---|---|
| European Union EU | 未找到匹配项 | 0 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review. |
| Great Britain GB | 未找到匹配项 | 0 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework. |
| Canada CA | Prohibited | 1打开记录 1 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | 请查看每条关联记录及其确切条件。 |
| New Zealand NZ | 未找到匹配项 | 0 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative. |
| ASEAN ASEAN | 未找到匹配项 | 0 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Regional annex coverage does not replace member-state implementation dates, notifications or national deviations. |
| China CN | 未找到匹配项 | 0 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately. |
| Japan JP | 未找到匹配项 | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | 未找到匹配项 | 0 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Korean source wording is canonical and other positive lists/notices may still apply to the formulation. |
| United States US | 未找到匹配项 | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | 未找到匹配项 | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | 未找到匹配项 | 0 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026. |
| India IN | 未找到匹配项 | 0 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | The standards are separate controlled publications; absence from a locally indexed excerpt is not permission. |
| Saudi Arabia SA | 未找到匹配项 | 0 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply. |
匹配的市场记录和条件
化学身份与性质

TrifluoroMethyl Dechloro
- IUPAC 名称
- (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
- 分子式
- C25H34F3NO5
- 分子量
- 485.5 g/mol
- 精确质量
- 485.23890767 Da
- XLogP3
- 3.0
- 拓扑极性表面积
- 99.0 Ų
- 氢键供体
- 4
- 氢键受体
- 8
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
来自其他科学数据库的证据
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录
科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。
其他来源的覆盖范围和匹配状态
| 来源 | 结果 | 已检查 |
|---|---|---|
| EMBL-EBI ChEBI | 无精确记录 | 2026-08-31 |
| NIH PubChem PUG-View | 精确匹配 | 2026-08-31 |
已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Unoprostone
Unoprostone is a ketone, an oxo monocarboxylic acid and a prostaglandins Falpha. It has a role as an antihypertensive agent and an antiglaucoma drug. — ChEBI
- IUPAC 名称
- (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid
- 分子式
- C22H38O5
- 分子量
- 382.5 g/mol
- 精确质量
- 382.27192431 Da
- XLogP3
- 3.7
- 拓扑极性表面积
- 94.8 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 4
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:39455
- ChEMBL:CHEMBL1201407
- EPA DTXSID:DTXSID80905120
- PubMed:14733708
来自其他科学数据库的证据
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Signal: Danger 来源: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity] 来源: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P203, P280, P318, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 来源: European Chemicals Agency (ECHA)
映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录
科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。
其他来源的覆盖范围和匹配状态
| 来源 | 结果 | 已检查 |
|---|---|---|
| NIH PubChem PUG-View | 精确匹配 | 2026-08-31 |
已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

17-phenyl-trinor-PGF2alpha isopropyl ester
17-phenyl-trinor-PGF2alpha isopropyl ester is a prostanoid. — ChEBI
- IUPAC 名称
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]hept-5-enoate
- 分子式
- C26H38O5
- 分子量
- 430.6 g/mol
- 精确质量
- 430.27192431 Da
- XLogP3
- 3.8
- 拓扑极性表面积
- 87.0 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:137717
- ChEMBL:CHEMBL2111623
- EPA DTXSID:DTXSID801365461
- PubMed:10634944
来自其他科学数据库的证据
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Signal: Danger 来源: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302+H312+H332 (100%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]; H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H312 (100%): Harmful in contact with skin [Warning Acute toxicity, dermal]; H332 (100%): Harmful if inhaled [Warning Acute toxicity, inhalation]; H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity] 来源: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P203, P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 来源: European Chemicals Agency (ECHA)
映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录
科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。
其他来源的覆盖范围和匹配状态
| 来源 | 结果 | 已检查 |
|---|---|---|
| NIH PubChem PUG-View | 精确匹配 | 2026-08-31 |
已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Latanoprost
Latanoprost is a prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an antihypertensive agent, an antiglaucoma drug and a prodrug. It is a triol, an isopropyl ester and a prostaglandins Falpha. It is functionally related to a latanoprost free acid. — ChEBI
- IUPAC 名称
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
- 分子式
- C26H40O5
- 分子量
- 432.6 g/mol
- 精确质量
- 432.28757437 Da
- XLogP3
- 4.3
- 拓扑极性表面积
- 87.0 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:6384
- ChEMBL:CHEMBL1051
- EPA DTXSID:DTXSID1041057
- PubMed:29921209
- PubMed:25811541
- PubMed:25328381
- PubMed:23956101
- PubMed:20019365
- PubMed:19403113
- PubMed:18721251
- PubMed:18166407
- PubMed:17539800
- PubMed:17459480
- PubMed:17416939
- PubMed:17102001
来自其他科学数据库的证据
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Boiling Point: 583.8 来源: DrugBank
- pKa: 4.88 来源: DrugBank
- LogP: 3.98 来源: DrugBank
- LogP: 4.4 来源: Human Metabolome Database (HMDB)
- Physical Description: Liquid 来源: Human Metabolome Database (HMDB)
- Solubility: 1.29e-02 g/L 来源: Human Metabolome Database (HMDB)
- Note: This chemical does not meet GHS hazard criteria for 0.7% (1 of 145) of reports. 来源: European Chemicals Agency (ECHA)
- Signal: Danger 来源: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H300 (63.4%): Fatal if swallowed [Danger Acute toxicity, oral]; H301 (11%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (62.1%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] 来源: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 145 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 1 of 145 reports by companies.; There are 15 notifications provided by 144 of 145 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 来源: European Chemicals Agency (ECHA)
- Toxicity Summary: Researchers found no carcinogenesis or mutagenesis with latanoprost, and the drug did not affect fertility in animal studies. However, latanoprost was noted to cause a chromosomal aberration in treated human lymphocytes. Intravenous infusion of 3 μg/kg of latanoprost in healthy volunteers produced plasma concentrations 200 times higher than during clinical treatment with latanoprost ophthalmic solution, and researchers identified no ADR. There is no evidence to establish a correlation between latanoprost administration and ocular or cutaneous melanoma.; Intravenous infusion of 5.5 to 10 μg/kg resulted in fatigue, sweating, dizziness, nausea, and abdominal pain. According to the manufacturer's labeling, treatment should be symptomatic if there is an overdosage with latanoprost ophthalmic solution. 来源: StatPearls
- Uses: Use (kg) in USA (2002): 1; Consumption (g per capita) in the USA (2002): 3.3e-06; Calculated removal (%): 100 来源: NORMAN Suspect List Exchange
映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录
科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。
其他来源的覆盖范围和匹配状态
| 来源 | 结果 | 已检查 |
|---|---|---|
| NIH PubChem PUG-View | 精确匹配 | 2026-08-31 |
已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Bimatoprost
Bimatoprost is a monocarboxylic acid amide. It has a role as an antihypertensive agent and an antiglaucoma drug. — ChEBI
- IUPAC 名称
- (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
- 分子式
- C25H37NO4
- 分子量
- 415.6 g/mol
- 精确质量
- 415.27225866 Da
- XLogP3
- 2.8
- 拓扑极性表面积
- 89.8 Ų
- 氢键供体
- 4
- 氢键受体
- 4
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:51230
- ChEMBL:CHEMBL1200963
- EPA DTXSID:DTXSID30895042
- PubMed:29854658
- PubMed:20463804
- PubMed:19874254
- PubMed:19403113
- PubMed:18523093
- PubMed:18452763
- PubMed:17724194
- PubMed:17721551
- PubMed:17459480
- PubMed:16808680
- PubMed:16804825
- PubMed:16644608
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Isopropyl Cloprostenate
- IUPAC 名称
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
- 分子式
- C25H35ClO6
- 分子量
- 467.0 g/mol
- 精确质量
- 466.2122165 Da
- XLogP3
- 3.8
- 拓扑极性表面积
- 96.2 Ų
- 氢键供体
- 3
- 氢键受体
- 6
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Travoprost
Travoprost is the isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol. It has a role as an antihypertensive agent, an antiglaucoma drug, a prodrug, a prostaglandin receptor agonist and an ophthalmology drug. It is an isopropyl ester, a prostaglandins Falpha and a member of (trifluoromethyl)benzenes. It is functionally related to a fluprostenol. — ChEBI
- IUPAC 名称
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
- 分子式
- C26H35F3O6
- 分子量
- 500.5 g/mol
- 精确质量
- 500.23857332 Da
- XLogP3
- 4.1
- 拓扑极性表面积
- 96.2 Ų
- 氢键供体
- 3
- 氢键受体
- 9
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:746859
- ChEMBL:CHEMBL1200799
- EPA DTXSID:DTXSID80896948
- PubMed:19929706
- PubMed:19403113
- PubMed:19038618
- PubMed:18983226
- PubMed:18837686
- PubMed:18452763
- PubMed:15321024
- PubMed:9038626
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Tafluprost
Tafluprost is a prostaglandin Falpha that is prostaglandin F2alpha in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side-chain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It has a role as a prostaglandin receptor agonist. It is an isopropyl ester, a prostaglandins Falpha and an organofluorine compound. It is functionally related to a prostaglandin F2alpha. — ChEBI
- IUPAC 名称
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
- 分子式
- C25H34F2O5
- 分子量
- 452.5 g/mol
- 精确质量
- 452.23743050 Da
- XLogP3
- 4.5
- 拓扑极性表面积
- 76.0 Ų
- 氢键供体
- 2
- 氢键受体
- 7
- 共价单元
- 1
- 已定义的立体中心
- 4
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:66899
- ChEMBL:CHEMBL1963683
- EPA DTXSID:DTXSID401021504
- PubMed:21916788
- PubMed:21858491
- PubMed:19477946
- PubMed:15037111
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Prostacyclin
Prostaglandin I2 is a prostaglandins I. It has a role as a mouse metabolite. It is a conjugate acid of a prostaglandin I2(1-). — ChEBI
- IUPAC 名称
- (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
- 分子式
- C20H32O5
- 分子量
- 352.5 g/mol
- 精确质量
- 352.22497412 Da
- XLogP3
- 2.9
- 拓扑极性表面积
- 87.0 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:15552
- ChEMBL:CHEMBL1139
- EPA DTXSID:DTXSID5022988
- PubMed:15962942
- PubMed:11999132
- PubMed:10952683
- PubMed:372237
- PubMed:12538
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Prostaglandin E2
Prostaglandin E2 is prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. It has a role as an oxytocic, a mouse metabolite and a human metabolite. It is a conjugate acid of a prostaglandin E2(1-). — ChEBI
- IUPAC 名称
- (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
- 分子式
- C20H32O5
- 分子量
- 352.5 g/mol
- 精确质量
- 352.22497412 Da
- XLogP3
- 2.8
- 拓扑极性表面积
- 94.8 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 4
又称
另有 16 个已报告名称
外部数据库标识符
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

- IUPAC 名称
- (Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid
- 分子式
- C22H29ClO6
- 分子量
- 424.9 g/mol
- 精确质量
- 424.1652663 Da
- XLogP3
- 2.7
- 拓扑极性表面积
- 107.0 Ų
- 氢键供体
- 4
- 氢键受体
- 6
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:177470
- EPA DTXSID:DTXSID50860575
- EPA DTXSID:DTXSID7048372
- PubMed:11999132
- PubMed:10634944
- PubMed:9694973
- PubMed:1216432
- PubMed:574679
- PubMed:565969
- PubMed:504688
- PubMed:452355
- PubMed:433124
- PubMed:433123
- PubMed:433103
- PubMed:295100
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Fluprostenol
Fluprostenol is an organofluorine compound that is racemic prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of its isopropyl ester prodrug, travoprost, are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. The isopropyl ester group of travoprost is hydrolysed to the biologically active free acid by esterases in the cornea. It has a role as an antihypertensive agent, an antiglaucoma drug, a female contraceptive drug, an abortifacient and a prostaglandin receptor agonist. It is a hydroxy monocarboxylic acid, a prostaglandins Falpha and a member of (trifluoromethyl)benzenes. — ChEBI
- IUPAC 名称
- (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic acid
- 分子式
- C23H29F3O6
- 分子量
- 458.5 g/mol
- 精确质量
- 458.19162313 Da
- XLogP3
- 2.9
- 拓扑极性表面积
- 107.0 Ų
- 氢键供体
- 4
- 氢键受体
- 9
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:60782
- ChEMBL:CHEMBL1201379
- EPA DTXSID:DTXSID7046122
- PubMed:33486071
- PubMed:21236357
- PubMed:16505027
- PubMed:15654655
- PubMed:11929662
- PubMed:11832489
- PubMed:10634944
- PubMed:9313928
- PubMed:8964835
- PubMed:7445532
- PubMed:6916556
- PubMed:6911921
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Misoprostol
7-[(1R,2R,3R)-3-hydroxy-2-(4-hydroxy-4-methyloct-1-enyl)-5-oxocyclopentyl]heptanoic acid methyl ester is a prostanoid. — ChEBI
- IUPAC 名称
- methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
- 分子式
- C22H38O5
- 分子量
- 382.5 g/mol
- 精确质量
- 382.27192431 Da
- XLogP3
- 3.7
- 拓扑极性表面积
- 83.8 Ų
- 氢键供体
- 2
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 3
又称
另有 16 个已报告名称
外部数据库标识符
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Alprostadil
Prostaglandin E1 is a prostaglandins E. It has a role as a vasodilator agent, an anticoagulant, a platelet aggregation inhibitor and a human metabolite. It is a conjugate acid of a prostaglandin E1(1-). — ChEBI
- IUPAC 名称
- 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
- 分子式
- C20H34O5
- 分子量
- 354.5 g/mol
- 精确质量
- 354.24062418 Da
- XLogP3
- 3.2
- 拓扑极性表面积
- 94.8 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 4
又称
另有 16 个已报告名称
外部数据库标识符
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Treprostinil
Treprostinil is a carboxylic acid and a carbotricyclic compound. It has a role as a cardiovascular drug, a vasodilator agent, an antihypertensive agent, a platelet aggregation inhibitor, a vitamin K antagonist and a human blood serum metabolite. — ChEBI
- IUPAC 名称
- 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
- 分子式
- C23H34O5
- 分子量
- 390.5 g/mol
- 精确质量
- 390.24062418 Da
- XLogP3
- 4.5
- 拓扑极性表面积
- 87.0 Ų
- 氢键供体
- 3
- 氢键受体
- 5
- 共价单元
- 1
- 已定义的立体中心
- 5
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:50861
- ChEMBL:CHEMBL1237119
- EPA DTXSID:DTXSID901021654
- PubMed:33440084
- PubMed:31917615
- PubMed:25542069
- PubMed:22480736
- PubMed:22291467
- PubMed:22114523
- PubMed:22055098
- PubMed:22043212
- PubMed:22034603
- PubMed:21988216
- PubMed:21606699
- PubMed:21280186
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。
官方来源与范围
导入自委员会实施决定 (EU) 2025/1175(数据集版本 EU 2025/1175)。词汇表为第 19(1)(g) 条所要求的成分表提供通用成分名称;它不是准许清单或安全清单。
打开官方决定